Ampakines

I’ll be honest — when I first stumbled across ampakines, I thought I’d found the holy grail of nootropics. A class of compounds specifically engineered to supercharge the brain’s primary learning receptors? That directly boost BDNF — the protein your brain uses to grow new connections? Sign me up.

Then I spent three months trying to actually get my hands on the good ones and realized the situation is a lot more complicated than the Reddit threads make it sound. The most promising ampakines are locked behind pharmaceutical development pipelines, and the ones you can buy come with serious question marks about safety.

Here’s what I’ve learned after years of digging through the research and experimenting with the ampakine-adjacent compounds that are actually available.

The Short Version: Ampakines are synthetic compounds that enhance cognition by modulating AMPA glutamate receptors — the brain’s fast-lane for excitatory signaling. The science behind them is solid, with strong preclinical evidence for memory enhancement, neuroprotection, and BDNF upregulation. The catch? Most of the best-studied compounds aren’t available to consumers, clinical trials in humans have been disappointing, and the research chemicals that are available (IDRA-21, sunifiram) have minimal human safety data. For most people, well-studied racetams like aniracetam offer a safer entry point into AMPA modulation.

What Are Ampakines?

Ampakines are a structurally diverse class of synthetic compounds that act as positive allosteric modulators of AMPA receptors in the brain. The name comes directly from the receptor they target — the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor), which handles fast excitatory neurotransmission throughout your central nervous system.

Think of AMPA receptors as the brain’s highway on-ramps for information flow. Every time you learn something, recall a memory, or process a new experience, AMPA receptors are doing the heavy lifting. Ampakines make those on-ramps wider and faster.

They were developed in the early 1990s by Dr. Gary Lynch at the University of California, Irvine. Lynch co-founded Cortex Pharmaceuticals (later renamed RespireRx Pharmaceuticals) to bring these compounds to market. The first generation included CX516 (marketed as Ampalex), followed by increasingly potent successors: CX546, CX614, CX691 (farampator), CX717, CX1739, and CX1837.

Now, you might see ampakines listed alongside racetams, and there’s some logic to that. Older racetams like piracetam and aniracetam do modulate AMPA receptors and are sometimes called “first-generation ampakines.” But the term more precisely refers to the newer benzamide-derived CX-series compounds, which were specifically engineered to target AMPA receptors with far greater selectivity and potency. Related compounds like IDRA-21 and sunifiram also show ampakine-like properties but are structurally distinct.

One critical distinction worth understanding: ampakines fall into two categories that dramatically affect their safety profile.

High-impact ampakines (CX614, CX546, CX1837) strongly offset receptor desensitization and increase agonist binding affinity. They’re more potent for BDNF upregulation and neuroprotection — but carry meaningful seizure risk at therapeutic doses.

Low-impact ampakines (CX516, farampator, CX717, CX1739) only partially offset desensitization and don’t meaningfully alter binding affinity. Safer profile with no seizure effects at therapeutic doses, but weaker cognitive effects.

This distinction matters enormously and is something most nootropic discussions gloss over entirely.

How Do Ampakines Work?

Here’s the plain-English version: your brain communicates through electrical signals that jump between neurons. AMPA receptors are the gatekeepers for the fastest type of excitatory communication. Ampakines don’t barge through those gates — they hold them open a little longer when they’re already being used. More signal gets through, and it persists for a longer window.

Now the deeper science. Ampakines bind to allosteric sites on AMPA receptors — not the glutamate binding site itself, but a separate regulatory site. This slows receptor deactivation and reduces desensitization, extending the duration of excitatory postsynaptic potentials (EPSPs). Crucially, they only potentiate signaling in the presence of glutamate. They don’t activate receptors on their own, which is a big part of why they’re considered relatively safe compared to direct agonists.

This leads to a cascade of downstream effects:

Long-term potentiation (LTP) enhancement. By prolonging AMPA receptor currents, ampakines facilitate LTP — widely considered the cellular mechanism behind memory consolidation. LTP stabilization depends on actin polymerization in dendritic spines, which ampakines actively promote. This is the “hardware upgrade” for learning.

BDNF upregulation — the big one. Ampakines increase brain-derived neurotrophic factor mRNA and protein levels, particularly in the hippocampus. BDNF is essentially fertilizer for your brain — it promotes dendritic growth, synaptic plasticity, neuronal survival, and new protein synthesis in dendrites. This BDNF effect, which works through TrkB receptor activation and the mTOR signaling pathway, is considered the primary mechanism behind the neuroprotective and long-term cognitive benefits of ampakines.

Respiratory drive stimulation. Ampakines enhance glutamatergic signaling in brainstem respiratory centers, producing a respiratory stimulant effect that can counteract opioid-induced respiratory depression. This is actually the area generating the most current clinical interest — potentially saving lives during the opioid crisis.

Pro Tip: If BDNF upregulation is what you’re after, exercise remains the most robust and well-proven method. Ampakines offer a pharmacological route to a similar endpoint, but don’t skip the fundamentals. Regular aerobic exercise, quality sleep, and compounds like Lion’s Mane offer BDNF support with far more safety data behind them.

What the Research Actually Shows

Let me be straight with you: the preclinical data for ampakines is exciting. The human data is mostly disappointing. Understanding the gap between these two is essential.

The Strong Preclinical Evidence

In animal studies, ampakines consistently improve learning and memory across multiple experimental paradigms. CX1837 enhanced synaptic transmission in hippocampal slices and dose-dependently boosted LTP. CX1739 showed pro-cognitive effects in rodent models. IDRA-21 demonstrated 10-30x greater potency than aniracetam in reversing cognitive deficits caused by alprazolam and scopolamine.

The neuroprotection data is particularly compelling. In a Huntington’s disease mouse model, twice-daily injections of a short half-life ampakine normalized BDNF levels, actin polymerization, and LTP (published in PNAS, 2009). CX1837 showed potential to slow Alzheimer’s progression and reverse ischemic stroke deficits through chronic BDNF elevation. Ampakines have also demonstrated antidepressant activity in animal models.

The Disappointing Human Reality

CX516 was the first to reach human trials, and the initial results looked promising — a small 4-week trial in 19 schizophrenia patients on clozapine showed improved attention and memory with effect sizes of 0.6-1.0. Then larger, better-designed follow-up studies found CX516 didn’t differ from placebo. It also failed Phase 2 trials for mild cognitive impairment, Alzheimer’s disease, and Fragile X syndrome. The likely culprit? Low potency, a short half-life, and extensive metabolism — not necessarily a failure of the ampakine concept itself.

CX717 showed more promise. At 800mg twice daily, it demonstrated superior efficacy versus placebo on ADHD Rating Scale measures across both inattentive and hyperactivity subscales. Across 281 subjects in 7 Phase 1/2 trials, there were no deaths, serious adverse events, or dose-limiting adverse events. It entered clinical development for ADHD, but complete results were never published.

Farampator (CX691) produced mixed results — some cognitive effects in healthy elderly volunteers, but also paradoxically impaired episodic memory. A 2025 study did find it had an antipsychotic-like pharmacological profile, suggesting potential for schizophrenia treatment.

CX1739 is the current bright spot, though its focus has shifted to respiratory applications. In a Phase 2A study, 300mg and 900mg doses significantly antagonized opioid-induced respiratory depression (p<0.005 and p<0.001 respectively), and it was safe and well-tolerated alongside opioids.

Reality Check: The human clinical data for cognitive enhancement with ampakines is, frankly, underwhelming. Animal models showed enormous promise that hasn’t translated well to humans — at least not yet. Newer compounds with better pharmacokinetic profiles (CX1837, CX1739) are more promising, but they remain in development pipelines. If someone tells you ampakines are “proven brain boosters,” they’re cherry-picking the preclinical data.

How to Take Ampakines

Here’s where things get tricky. Most ampakine compounds (the CX-series) simply aren’t available to consumers. What is available exists in a regulatory gray area with minimal human safety data.

CX-Series Compounds (Not Consumer-Available — For Reference Only)

Consumer-Available Ampakine-Adjacent Compounds

IDRA-21 is sold through research chemical vendors as “not for human consumption.” Self-experimenters typically report using 10-20mg daily, taken in the morning due to its stimulant-like effects. What makes IDRA-21 unusual is its remarkably long duration — effects persist up to 48 hours after a single dose. This is not FDA-approved and carries real risk.

Sunifiram (DM-235) is reported at 5-10mg sublingually in nootropic communities, with rapid but short-lived effects. It has never undergone toxicology testing or any human clinical trials. It is not approved anywhere in the world.

If You Do Choose to Experiment

• Start at the lowest reported dose and assess tolerance over several days
• Morning dosing is preferred due to stimulatory effects
• Some nootropic communities recommend cycling (5 days on / 2 days off, or 4 weeks on / 1 week off) to prevent tolerance, though this is purely anecdotal
• No specific food interactions have been established
• Keep a detailed journal of effects and any side effects

Important: The consumer-available ampakine compounds exist in a regulatory gray area with virtually no human safety data. If you choose to experiment, you are genuinely acting as your own guinea pig. This is not the same as trying a well-studied racetam or a common supplement. Proceed with extreme caution, start low, and seriously consider whether the risk-reward calculation makes sense for your situation.

Side Effects and Safety Concerns

From Human Clinical Trials

The most commonly reported side effects across the CX-series compounds include headache, drowsiness, nausea, and — paradoxically — impaired episodic memory at higher doses. CX516 caused fatigue, insomnia, and stomach discomfort. CX717, across 281 subjects in 7 trials, was generally well-tolerated with no serious adverse events. CX1739 showed adverse events comparable to placebo.

The Serious Concerns

Seizure risk is the elephant in the room. High-impact ampakines (CX614, CX546) have induced seizures in rodents at or near therapeutic doses — this halted clinical development of several compounds. Low-impact ampakines (CX516, CX717, CX691, CX1739) do not show seizurogenic effects at therapeutic doses, which is why the distinction between high-impact and low-impact matters so much.

For context, perampanel — an AMPA receptor antagonist (the opposite of an ampakine) — is used to treat epilepsy. Ampakines work in the exact opposite direction. Anyone with epilepsy or a history of seizures should consider ampakines strongly contraindicated.

Glutamate excitotoxicity is a theoretical risk with any compound that enhances glutamatergic transmission. At excessive doses, overactivation of glutamate receptors can damage or kill neurons. With gray-market compounds lacking proper dosing guidance, this isn’t just theoretical.

Who Should Avoid Ampakines

• Anyone with epilepsy or history of seizures — strong contraindication
• Pregnant or nursing women — zero safety data exists
• Children — no pediatric data for any ampakine compound
• People taking anti-epileptic medications — ampakines may counteract their effects
• Anyone on antipsychotics without medical supervision — synergistic interactions can be unpredictable

Drug Interactions to Watch

Ampakines interact synergistically with antipsychotics, potentially enhancing low doses dramatically. They counteract opioid-induced respiratory depression (being developed therapeutically). Combining them with other glutamatergic drugs or stimulants could produce excessive excitatory activity.

Stacking Ampakines

Evidence-Based Combinations

The most practical way most people will encounter ampakine-like effects is through racetam stacking. Aniracetam is itself an ampakine-type racetam and is commonly combined with piracetam at a 4:1 ratio (piracetam:aniracetam). The PAO stack — Piracetam + Aniracetam + Oxiracetam — is popular in nootropic communities, with all three compounds offering some degree of AMPA modulation.

Choline support is commonly recommended alongside any AMPA-modulating compound. Alpha-GPC or citicoline paired with racetam-type ampakines supports acetylcholine synthesis and may help prevent the headaches commonly reported with these compounds.

What to Absolutely Avoid

• Multiple high-potency ampakines together. Stacking IDRA-21 with sunifiram or other potent AMPA modulators creates unpredictable risk of excessive glutamatergic activity.
• IDRA-21 combined with anything ampakine-like. Its 48+ hour duration means you’re stacking on top of an already-active compound for days.
• Ampakines with pro-convulsant substances. The seizure risk compounds with anything that lowers your seizure threshold.
• Ampakines with strong glutamate agonists. Excitotoxicity risk becomes real when you’re hitting the glutamate system from multiple angles.

Insider Tip: If you’re interested in the AMPA-modulating effects of ampakines but want to play it safe, a well-dosed aniracetam protocol (750mg twice daily) with Alpha-GPC (300mg) is going to give you the most AMPA-relevant benefit with the most human safety data behind it. It’s not as sexy as cutting-edge research chemicals, but it’s what I’d recommend to a friend.

My Take

Here’s my honest assessment after years of following ampakine research and experimenting with the accessible compounds in this class: ampakines are one of the most scientifically elegant approaches to cognitive enhancement ever developed. The mechanism is clean, the downstream effects (especially BDNF upregulation) are exactly what you’d want from a nootropic, and the preclinical data is genuinely exciting.

But — and this is a big but — the clinical translation has been disappointing. Early compounds failed for pharmacokinetic reasons, and the newer, more promising ones are stuck in development pipelines that most of us can’t access. The consumer-available options (IDRA-21, sunifiram) are potent but carry real risk. You’re essentially beta-testing compounds that haven’t undergone proper human safety evaluation.

Who ampakines are best for: Experienced nootropic users who have already optimized their foundational health, have tried well-studied racetams, and understand the risk profile of research chemicals. People specifically interested in BDNF-mediated neuroprotection for conditions like neurodegenerative disease may find the research worth following closely.

Who should try something else: Beginners, anyone looking for their first nootropic, people with seizure history or on medications that interact with glutamatergic signaling. If you haven’t tried aniracetam, Bacopa Monnieri, or Lion’s Mane yet, start there. You’ll get meaningful cognitive benefits with dramatically more safety data.

The most exciting near-term application for ampakines isn’t cognitive enhancement at all — it’s reversing opioid-induced respiratory depression, which could save thousands of lives. Sometimes the most important breakthroughs come from a direction nobody expected.

For now, I’m watching this space closely. When a well-characterized, properly tested ampakine with good bioavailability and a clean safety profile becomes available, it’ll be a game-changer. We’re not there yet — but the science says we’re heading in the right direction.